The Mutation Frequency of Feline Immunodeficiency Virus Enhanced by 3′-Azido-3′-deoxythymidine

Journal of Acquired Immune Deficiency Syndromes

Volumn 12, Issue 1, 1996, Pages 26-32

  LaCasse, Rachel A ^a   Remington, Kathryn M ^a   North, Thomas W ^a  

^a UNIVERSITY OF MONTANA   (United States)

Author keywords

Antiviral drugs; Feline immunodeficiency virus; Lentivirus mutation frequency

Indexed keywords

DIDANOSINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CAT DISEASE; DRUG EFFECT; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIVIRAL AGENTS; BROMODEOXYURIDINE; CATS; CELL LINE; DIDANOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE FREQUENCY; IMMUNODEFICIENCY VIRUS, FELINE; KIDNEY; MUTATION; VIRUS CULTIVATION; ZALCITABINE; ZIDOVUDINE;

FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; FELIS CATUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

EID: 0030007820     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199605010-00004     Document Type: Article

References (39)

1. Coffin JM. Genetic variation in AIDS virus. Cell 1986;46:1-4.
2. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988;242:1168-71.
3. Roberts JD, Benebek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science 1988;242:1171-3.
4. Nowak MA, Anderson RM, McLean AR, Wolfs TFW, Goudsmit J, May RM. Antigenic diversity thresholds and the development of AIDS. Science 1991;254:963-9.
5. Varela-Echavarria A, Garvey N, Preston BD, Dougherty JP. Comparison of Moloney murine leukemia virus mutation rate with the fidelity of its reverse transcriptase in vitro. J Biol Chem 1992;267:24681-8.
6. Wainberg MA, Gu Z, Gao Q, et al. Clinical correlates and molecular basis of HIV-1 drug resistance. J Acquir Immune Defic Syndr 1993;6(suppl. 1):S36-S46.
7. Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiviral agents. Antimicrob Agents Chemother 1993;37:1207-13.
8. Chesebro B, Wehrly K, Nishio J, Perryman S. Macrophagetropic immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homology in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J Virol 1992;66:6547-54.
9. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-9.
10. Monk RJ, Malik FG, Stokesberry D, Evans LH. Direct determination of the point mutation rate of a murine retrovirus. J Virol 1992;66:3683-9.
11. Pathak VK, Temin HM. 5-Azacytidine and RNA secondary structure increase the retrovirus mutation rate. J Virol 1992;66:3093-100.
12. Remington KM, Chesebro B, Wehrly K, Pedersen NC, North TW. Mutants of feline immunodeficiency virus resistant to 3′-azido-3′deoxythymidine. J Virol 1991;65:308-12.
13. Remington KM, Zhu Y-Q, Phillips TR, North TW. Rapid phenotypic reversion of AZT-resistant mutants of feline immunodeficiency virus without loss of drug-resistant reverse transcriptase. J Virol 1994;68:632-7.
14. Gobert JD, Remington KM, Zhu Y-Q, North TW. Multiple drug-resistant mutants of feline immunodeficiency virus selected with 2′,3′-dideoxyinosine alone and in combination with 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 1994;38:861-4.
15. Larder BA, Darby G, Richmann DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-4.
16. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-8.
17. Novotney C, English RV, Housman J, et al. Lymphocyte population changes in cats naturally infected with feline immunodeficiency virus. AIDS 1990;4:1213-8.
18. Pedersen NC, Barlough JE. Clinical overview of feline immunodeficiency virus. J Am Vet Med Assoc 1991;199:1298-305.
19. Pedersen NC, Ho EW, Brown ML, Yamamoto JK. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987;235:790-3.
20. Ishida T, Tomoda I. Clinical stages of feline immunodeficiency virus infection. Jpn J Vet Sci 1990;52:645-8.
21. Yamamoto JK, Sparger E, Ho EW, et al. Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am J Vet Res 1988;49:1246-58.
22. Torten M, Franchini M, Barlough JE, George JW, Mozes E, Lutz H, Pedersen NC. Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus. J Virol 1991;65:2225-30.
23. Cronn RC, Remington KM, Preston BD, North TW. Inhibition of reverse transcriptase from feline immunodeficiency virus by analogs of 2′-deoxyadenosine-5′-triphosphate. Biochem Pharmacol 1992;44:1375-81.
24. North TW, Cronn RC, Remington KM, Tandberg RT. Direct comparisons of inhibitor sensitivities of reverse transcriptase from feline and human immunodeficiency viruses. Antimicrob Agents Chemother 1990;34:1505-7.
25. North TW, Cronn RC, Remington KM, Tandberg RT, Judd RC. Characterization of reverse transcriptase from feline immunodeficiency virus. J Biol Chem 1990;265:5121-8.
26. North TW, North GLT, Pedersen NC. Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother 1989;33:915-9.
27. Mathews CK. Bacteriophage biochemistry. New York: Van Nostrand Reinhold Company, 1971:70-1,74.
28. North TW, LaCasse RA. Testing anti-HIV drugs in the FIV model. Nature Med 1995;1:410-1.
29. Talbott RL, Sparger EE, Lovelace KM, et al. Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci USA 1989;86:5743-7.
30. Freese E. The specific mutagenic effect of base analogues on phage T4. J Mol Biol 1959;1:87-105.
31. Retrovir package insert, Burroughs Wellcome Co., Research Triangle Park, North Carolina, 1990.
32. Coffin JM. Genetic diversity and evolution of retroviruses. Curr Topics Microbiol Immunol 1992;176:143-64.
33. Coffin JM. Genetic variation in retroviruses. In: Kurstak E, Marusyk RG, Murphy FA, Van Regenmortel MHV, eds. Applied virology research. New York: Plenum Press, 1990;2:11-33.
34. Collier AC, Bozzette S, Coombs RW, et al. Low dose zidovudine in HIV infection. N Engl J Med 1990;321:1626-31.
35. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency infection: results of the Veteran Affairs Cooperative Study. N Engl J Med 1992;326:437-43.
36. Frick LW, Nelson DJ, St. Clair MH, Furman PA, Krenitsky TA. Effects of 3′-azido-3′-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cells. Biochem Biophys Res Commun 1988;154:124-9.
37. Fridland A, Connelly MC, Ashmun R. Relationship of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3′-azido-3′-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM). Mol Pharmacol 1990;37:665-70.
38. Furman PA, Fyfe JA, St. Clair MH, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986;83:8333-7.
39. Meuth M. The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells. Exp Cell Res 1989;181:305-16.